Arcutis Biotherapeutics, Inc. (ARQT)

Arcutis Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	166.54	29.19	3.69	-	-
Other Revenue	30	30.42	-	-	-
Revenue	196.54	59.61	3.69	-	-
Revenue Growth (YoY)	229.73%	1517.09%	-	-	-
Cost of Revenue	19.13	4.99	0.75	-	-
Gross Profit	177.41	54.62	2.93	-	-
Selling, General & Admin	229.39	185.15	122.12	60.97	21.34
Research & Development	76.42	110.58	182.44	145.56	115.31
Operating Expenses	305.81	295.72	304.56	206.53	136.65
Operating Income	-128.4	-241.1	-301.63	-206.53	-136.65
Interest Expense	-27.17	-29.71	-15.65	-	-
Interest & Investment Income	16.17	11.79	5.82	0.17	0.97
Pretax Income	-139.39	-259.03	-311.46	-206.36	-135.68
Income Tax Expense	0.65	3.11	-	-	-
Net Income	-140.04	-262.14	-311.46	-206.36	-135.68
Net Income to Common	-140.04	-262.14	-311.46	-206.36	-135.68
Shares Outstanding (Basic)	121	69	55	49	36
Shares Outstanding (Diluted)	121	69	55	49	36
Shares Change (YoY)	74.53%	25.94%	11.39%	38.52%	1835.11%
EPS (Basic)	-1.16	-3.78	-5.66	-4.18	-3.80
EPS (Diluted)	-1.16	-3.78	-5.66	-4.18	-3.80
Free Cash Flow	-112.3	-247.49	-258.05	-175.62	-113.35
Free Cash Flow Per Share	-0.93	-3.57	-4.69	-3.56	-3.18
Gross Margin	90.27%	91.63%	79.54%	-	-
Operating Margin	-65.33%	-404.49%	-8183.04%	-	-
Profit Margin	-71.25%	-439.79%	-8449.76%	-	-
Free Cash Flow Margin	-57.14%	-415.20%	-7000.76%	-	-
EBITDA	-125.8	-239.58	-300.69	-206.08	-136.52
EBITDA Margin	-64.01%	-	-	-	-
D&A For EBITDA	2.6	1.52	0.93	0.45	0.12
EBIT	-128.4	-241.1	-301.63	-206.53	-136.65
EBIT Margin	-65.33%	-	-	-	-
Revenue as Reported	196.54	59.61	3.69	-	-

Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q